BUZZ-Oncolytics Biotech Inc: Lead drug gets orphan drug status

Wed Feb 11, 2015 7:36am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian biotech company's U.S.-listed shares up 16.6 pct at 54 cents premarket

** Company says U.S. FDA grants its lead drug, reolysin, orphan drug status for the treatment of ovarian cancer

** Orphan designation is granted to drugs developed to treat rare diseases, offering the developer several incentives, including seven-year marketing exclusivity in the U.S.

** Reolysin is being tested for use in a plethora of cancers, both alone and in combination with chemotherapy

** Up to Tuesday's close, U.S.-listed stock had lost nearly 34 pct of its value since Nov.6, when it posted a smaller-than-expected Q3 loss